search
cancer patients
Trends
- 1Iran's pharmaceutical crisis deepens amid sanctions and war costs●A Hebrew newspaper reports that US sanctions, inflation, currency shortages, and the costs of war have exacerbated Iran'
A Hebrew newspaper reports that Iran is facing a worsening pharmaceutical crisis, with shortages affecting roughly 800 types of medication. The missing drugs range from cancer and heart disease treatments to insulin and migraine medicine. The report attributes the crisis to US sanctions, high inflation, currency shortages, and the mounting costs of war, leaving many Iranian patients struggling to obtain essential treatment.
- 2Indoor gardening lifts mental health of cancer patients▼Indoor gardening improves mental health and quality of life for cancer patients https://www. psypost.org/indoor-gardenin
New research suggests indoor gardening can improve mental health and quality of life for cancer patients. The findings indicate that tending plants at home offers a low-cost, accessible way to support emotional wellbeing during treatment. Health and psychology commentators are sharing the study, with many noting gardening's therapeutic potential alongside conventional care for people facing cancer.
- 3Indoor gardening boosts mental health for cancer patients●Indoor gardening improves mental health and quality of life for cancer patients
New research indicates that indoor gardening can improve mental health and overall quality of life for cancer patients. The findings suggest that tending plants indoors offers therapeutic benefits, potentially easing anxiety, depression, and stress during treatment. Health writers highlight the study as a low-cost, accessible way to support patients' emotional wellbeing alongside medical care.
- 4Why Cancer Drug Clinical Trials Take So Long●Opinion | Why Do Clinical Trials for Cancer Drugs Take So Long?
The New York Times has published an opinion piece examining why clinical trials for cancer drugs take so long to complete. The article addresses the lengthy timelines between developing experimental cancer therapies and making them available to patients, a source of ongoing frustration for patients, families and researchers. Discussion centers on whether regulatory processes, patient recruitment and trial design could be accelerated without compromising safety.